Ram Dharma, Rajappa Suhas K, Selvakumar Veda P, Shukla Himanshu, Goel Ashish, Kumar Rajeev, Kumar Kapil
Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Department of Breast Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
South Asian J Cancer. 2017 Oct-Dec;6(4):141-143. doi: 10.4103/sajc.sajc_2_17.
Present study was done with an aim to analyse the clinicopathological and survival characteristics of male breast cancer patients.
We did a retrospective review of our database and analysed total 27 patients who presented to breast oncology unit of Rajiv Gandhi cancer centre and research institute from January 2010 to April 2016.
Most common stage at presentation in our study was in stage II. The median follow up was 32.75 months. The actuarial 5-year survival was 92.30% and DFS was 76.30%. Only hormone receptor status was found as a significant prognostic variable among the prognostic factors studied for disease free survival.
Carcinoma breast in male is a relatively rare disease and management principles are translated from our understanding of breast cancer in women. A relatively early stage at presentation is a contrasting finding of our series which may be responsible for a significantly better actuarial 5 year survival rates.
本研究旨在分析男性乳腺癌患者的临床病理特征及生存特征。
我们对数据库进行了回顾性分析，研究对象为2010年1月至2016年4月期间在拉吉夫·甘地癌症中心和研究所乳腺肿瘤科室就诊的27例患者。
在我们的研究中，最常见的就诊分期为II期。中位随访时间为32.75个月。精算5年生存率为92.30%，无病生存率为76.30%。在研究的无病生存预后因素中，仅激素受体状态被发现是一个显著的预后变量。
男性乳腺癌是一种相对罕见的疾病，其治疗原则是基于我们对女性乳腺癌的认识。就诊时相对早期是我们这组病例的一个不同寻常的发现，这可能是精算5年生存率显著更高的原因。
